OPTIMIZING PATIENT CARE AND REDUCING READMISSIONS AT CAREPLUS HOSPITAL THROUGH PREDICTIVE ANALYTICS

AI & ML ASSIGNMENT



Name: Khushi Malik Roll no. 15A Submitted to: Dr. Nitin Mehr

Problem Statement

HealthFirst Multispeciality Hospital is concerned about the increasing number of diabetic patients returning for readmission within a short time after discharge. The hospital aims to identify patterns and predictors of patient readmission to implement preventive measures, improve patient care, and optimize resource allocation.

Objective and Rationale

The objective of this analysis is to predict whether a diabetic patient is likely to be readmitted to the hospital after treatment. Early prediction will help the hospital management to take proactive actions such as follow-up consultations, personalized care, and patient education programs, thereby reducing operational costs and improving patient outcomes.

Methodology Adopted

- 1. **Data Collection:** A dataset containing information on diabetic patients' hospital visits, treatments, demographics, and outcomes was procured.
- 2. Data Understanding and Cleaning:
 - Cleaning and formatting were performed in Microsoft Excel.
 - \circ $\,$ The "Find and Replace" function was used to reform at categories.
 - Excel formulas were used to compute average values such as age ranges.
 - o Rows with missing values were removed entirely.

3. Data Models

- **Principal Component Analysis (PCA)** is used for dimensionality reduction, where the original dataset is transformed into a smaller set of uncorrelated variables, called principal components, which capture the most variance in the data. This helps in simplifying the model and reducing computational cost without losing critical information.
- **Random Forest** is an ensemble learning technique that builds multiple decision trees and combines their predictions. It enhances accuracy by reducing overfitting and variance, especially in complex datasets, making it a robust choice for classification tasks.
- **K-Means Clustering** is an unsupervised learning algorithm used to partition the dataset into K clusters based on feature similarities. It assigns each data point to the cluster with the nearest mean, helping in grouping similar data points and uncovering hidden patterns.
- Logistic Regression is a statistical model used for binary classification, where the relationship between the independent variables and the dependent variable is modeled using a logistic function. It's effective for predicting the probability of class membership, especially in cases with linear relationships between predictors and the outcome.

Data Set and Source

- **Dataset Used:** Diabetic patient hospital visit records.
- **Source:** UC Irvine Machine Learning Repository (customized and downloaded independently for academic analysis).

Principle Component Analysis (PCA)



Component	Standard Deviation	Proportion of Variance	Cumulative Variance
PC 1	1.540	0.264	0.264
PC 2	1.235	0.169	0.433
PC 3	1.037	0.120	0.552
PC 4	0.986	0.108	0.660
PC 5	0.950	0.100	0.761
PC 6	0.824	0.075	0.836
PC 7 PC 6	0.771	0.066	0.902
PC 8	0.711	0.056	0.958
PC 9	0.612	0.042	1.000

The first five components (PC1 to PC5) still explain 76.1% of the total variance, justifying their selection as the top five components.

Attribute	PC 1	PC 2	PC 3	PC 4	PC 5	PC 6	PC 7	PC 8	PC 9
Age median	0.272	-0.186	0.630	0.405	-0.006	-0.047	0.474	0.299	0.120
time_in_hospital(days)	0.468	0.008	-0.241	0.081	-0.043	0.599	0.323	-0.273	-0.420
num_lab_procedures	0.310	0.076	-0.574	0.432	-0.141	-0.400	-0.041	0.434	-0.111
num_procedures	0.368	-0.102	0.141	-0.682	0.171	-0.264	0.014	0.330	-0.401
num_medications	0.530	0.053	-0.156	-0.258	0.044	0.112	-0.027	-0.022	0.781
number_outpatient	-0.012	0.620	0.037	-0.162	-0.325	-0.387	0.489	-0.305	0.002
number_emergency	-0.034	0.398	-0.054	0.154	0.893	-0.027	0.123	0.004	-0.006
number_inpatient	0.022	0.628	0.246	0.005	-0.209	0.413	-0.337	0.462	-0.054
number_diagnoses	0.439	0.090	0.326	0.248	0.022	-0.275	-0.548	-0.482	-0.151

PC1: num_medications (26.4% Variance)

- Loading: 0.530 (positive, moderate).
- Interpretation: PC1 is driven by the number of medications, reflecting treatment complexity. Higher values indicate patients with multiple prescriptions, often linked to chronic conditions (e.g., diabetes, ICD-9: 250) or polypharmacy risks.

PC2: number_inpatient (16.9% Variance)

- Loading: 0.628 (positive, high).
- Interpretation: PC2 is dominated by the number of inpatient visits, indicating a history of severe or frequent hospitalizations (e.g., heart failure, ICD-9: 428).

PC3: age_median (12.0% Variance)

- Loading: 0.630 (positive, high).
- **Interpretation**: PC3 is strongly influenced by the median age, suggesting it represents the age-related risk profile of patients. Higher values indicate older patients, who are more vulnerable to complications.

PC4: num_procedures (10.8% Variance)

- Loading: -0.682 (negative, high).
- Interpretation: PC4 is inversely related to the number of medical procedures, indicating that fewer procedures align with this component. This may reflect less invasive treatment or stable conditions.

PC5: number_emergency (10.0% Variance)

- Loading: 0.893 (positive, very high).
- Interpretation: PC5 is heavily weighted by the number of emergency visits, representing acute care utilization and unstable health states.

Random Forest



	true NO	true >30	true <30	class precision
pred. NO	417	359	72	49.17%
pred. >30	51	49	16	42.24%
pred. <30	3	1	2	33.33%
class recall	88.54%	11.98%	2.22%	

Accuracy: 48.25% ± 2.65%

This means the model predicts the correct readmission status in about **48 out of 100 cases**, which is just slightly better than random guessing for a 3-class problem.

Interpretation

The Random Forest confusion matrix shows classification performance for predicting readmission timing: "NO" (not readmitted), ">30" (readmitted after 30 days), and "<30" (readmitted before 30 days). Accuracy is 48.25% (±2.65%), indicating moderate performance.

- **True NO (88.54% recall)**: 417 correctly predicted as not readmitted, but 359 misclassified as ">30" and 51 as ">30", showing over-prediction of readmission.
- **True >30 (11.98% recall)**: 49 correctly predicted, but 359 misclassified as "NO", reflecting poor sensitivity for late readmissions.
- **True <30 (2.22% recall)**: 16 correctly predicted, but 72 misclassified as "NO", indicating low detection of early readmissions.
- Precision: 49.17% ("NO"), 42.24% (">30"), 33.33% ("<30"), suggesting moderate reliability in predictions. The class imbalance (88.54% "NO" vs. 11.98% ">30" and 2.22% "<30") likely biases the model toward "NO".

Inferences

- The model excels at identifying non-readmitted patients but struggles with readmission timing, especially "<30" days, due to low recall
- Model needs better sensitivity for minority classes: Readmitted patients (especially within 30 days) are under-represented in predictions, likely due to class imbalance in the dataset.
- Improvement needed before real-world deployment: Without better recall for readmitted cases, relying solely on this model could lead to missed interventions and poor patient outcomes.

K-Mean: Cluster Distance Performance



To identify meaningful groupings in the dataset, K-Means clustering was applied. The elbow method was used to determine the optimal number of clusters. The distance (inertia) values for different values of k were plotted, showing a steep decline until k = 6, after which the curve begins to flatten, indicating diminishing returns in variance reduction. This inflection point suggests that 6 is the optimal number of clusters.

Elbow Method Observations:

- The distortion score drops significantly from k = 2 to k = 6.
- Beyond k = 6, the decrease in inertia becomes minimal.
- Hence, k = 6 is chosen as the ideal number of clusters.

Cluster Interpretation

Retrieve diabetic_dat	Select Attributes	Normalize	Clustering	Cluster Model Visualiz
	exa exa ori	exa exa ori pre	exa ciu ciu	mod vis res clu mod res nor res
Number of Clusters: 6				
Cluster 0 266				
number_emergency is on a	verage 100.00% smaller, r	number_outpatient is on a	average 78.96% smaller,	number_inpatient is on average 59.68% smaller
Cluster 1				
number_outpatient is on a	verage 15,444.87% larger,	number_inpatient is on a	verage 2,076.28% large	r, number_emergency is on average 100.00% smaller
Cluster 2				
number_inpatient is on ave	erage 1,047.93% larger, nu	mber_emergency is on av	verage 100.00% smaller	number_outpatient is on average 28.25% smaller
Cluster 3 413				
number_emergency is on a	verage <mark>100.00%</mark> smaller, r	number_outpatient is on a	average 54.83% smaller,	time_in_hospital(days) is on average 28.61% smaller
Cluster 4 247				
number_emergency is on a	verage <mark>100.00%</mark> smaller, t	ime_in_hospital(days) is o	on average 98.30% large	r, num_procedures is on average 82.84% larger
Cluster 5				
number_emergency is on a	verage 6,366.67% larger, i	number_outpatient is on a	average 1,019.23% large	er, number_inpatient is on average 397.44% larger

Cluster 0 (n = 266)

- **Emergency visits:** 100% lower (no emergency visits)
- Outpatient visits: 78.96% lower
- Inpatient visits: 59.68% lower

Interpretation:

These patients are relatively healthy, with significantly fewer hospital interactions across all types of visits. They might represent low-risk or well-managed chronic patients.

Cluster 1 (n = 3)

- **Outpatient visits:** 15,444.87% higher
- Inpatient visits: 2,076.28% higher
- Emergency visits: 100% lower (none)
 - Interpretation:

This small group represents **intensive-care or high-frequency patients**, visiting hospitals very frequently but avoiding emergency services. Likely under scheduled or long-term treatment.

Cluster 2 (n = 26)

- Inpatient visits: 1,047.93% higher
- Emergency visits: 100% lower
- Outpatient visits: 28.25% lower

Interpretation:

Patients in this cluster are primarily treated within hospitals (inpatients) but do not

frequently use emergency or outpatient services. Possibly long-term or post-operative inpatients.

Cluster 3 (n = 413)

- Emergency visits: 100% lower
- Outpatient visits: 54.83% lower
- Time in hospital: 28.61% shorter
 - Interpretation:

This largest cluster suggests **moderate-need patients**. They use fewer hospital resources, have shorter stays, and no emergency visits, indicating mild conditions or effective care.

Cluster 4 (n = 247)

- Emergency visits: 100% lower
- Time in hospital: 98.30% higher
- Procedures: 82.84% higher
 - Interpretation:

Patients here undergo **long hospital stays and many procedures**, without emergency visits. Likely suffering from chronic or complex conditions requiring consistent monitoring and interventions.

Cluster 5 (n = 15)

- **Emergency visits:** 6,366.67% higher
- Outpatient visits: 1,019.23% higher
- Inpatient visits: 397.44% higher
 - Interpretation:

These are **critical patients** who require frequent attention across all types of hospital services, especially emergency. They likely have acute conditions or repeated complications.

Logistics Regression



A Logistic Regression model was tested for CarePlus Hospital's readmission prediction, using features like age_median and number_emergency. The confusion matrix shows 0.00% accuracy, with all precision and recall at 0.00%, as 141 "NO" and 150 "YES" cases were misclassified as "Low," indicating complete failure to differentiate classes.

0.00%

0.00%

0.00%

Interpretation

class recall

0.00%

The poor performance likely stems from class imbalance, linear assumptions not fitting the data, or inadequate feature handling, contrasting with Random Forest's 48.25% accuracy.

Inferences

Logistic Regression is unsuitable due to its inability to capture non-linear patterns, suggesting a preference for ensemble methods like Random Forest.

Actionable Business Inferences for Strategic Decision Making.

Random Forest Insights

• The Random Forest model shows moderate accuracy, excelling at identifying nonreadmitted patients but struggling with early and late readmission detection due to class imbalance.

Action: Enhance follow-up care for misclassified readmitted patients using telehealth, focusing on key risk factors, and apply balancing techniques to improve detection of high-risk cases.

PCA Insights

• The PCA analysis highlights treatment complexity, hospitalization history, age-related risk, treatment intensity, and acute care utilization as key drivers of readmission.

Actions:

- Optimize medication regimens for patients with complex treatments through pharmacy reviews.
- Provide coordinated care for patients with frequent hospitalizations.
- Offer tailored support for older patients to address age-related risks.
- Monitor patients with low procedure counts for adequate post-discharge care.
- Implement emergency triage for patients with high acute care use to prevent readmissions.

Integrated Strategic Insights

- Prioritize Random Forest and PCA over Logistic Regression for robust predictions, reallocating resources to refine these models.
- Focus interventions on high-risk patient groups to improve outcomes and reduce penalties.
- Use real-time risk scoring from PCA and Random Forest to continuously adjust strategies and sustain readmission reductions.

Suggestions to the Healthcare Industry (CarePlus Hospital)

- 1. **Enhance Proactive Patient Care Programs**: Invest in comprehensive post-discharge care initiatives, such as telehealth monitoring and home health services, to support patients with chronic conditions, reducing readmission rates and improving long-term health outcomes across the industry.
- 2. Leverage Advanced Data Analytics: Adopt cutting-edge data analytics and predictive tools to identify at-risk patients early, enabling personalized interventions and optimizing resource allocation, which can set a new standard for healthcare efficiency and patient satisfaction.
- 3. **Foster Collaborative Care Networks**: Build strong partnerships with community healthcare providers, social services, and insurers to create integrated care pathways, ensuring seamless transitions and addressing social determinants of health, thereby elevating overall patient care quality and reducing costs.

Excel Sheet

										disc	harge_	time_in_h	num_lab_				number						
									admission	disp	osition	ospital(da	procedur	num_pro	num_med	number	o emerge	n number_i	number_d	i max_glu_	A1Cresul	metform	i repagli
encount	ter_id p	patient_nbr	race		gender	a	ge	Age median	type_id	_id		ys)	es	cedures	ications	utpatier	t cy	npatient	agnoses	serum	t	n	e
227	78392	8222157	Caucas	ian	Female	[0	0-10)	5	6	6	25	1	41	0	1		0	0	0	1 None	None	No	No
14	19190	55629189	Caucas	lan	Female	[]	10-20)	15	1	L	1	3	59	0	18		0	0	0	9 None	None	No	No
e	54410	86047875	African.	American	Female	[2	20-30)	25	1	L	1	2	11	5	13		2	0	1	6 None	None	No	No
50	00364	82442376	Caucas	ian	Male	[3	30-40)	35	1	1	1	2	44	1	. 16		0	0	0	7 None	None	No	No
1	16680	42519267	Caucas	ian	Male	[4	40-50)	45	1	1	1	1	51	0	8		0	0	0	5 None	None	No	No
3	35754	82637451	Caucas	ian	Male	[8	50-60)	55	2	2	1	3	31	6	16		0	0	0	9 None	None	No	No
5	55842	84259809	Caucas	ian	Male	[6	30-70)	65	3	3	1	4	70	1	. 21		0	0	0	7 None	None	Steady	No
e	63768 1	114882984	Caucas	ian	Male	[70-80)	75	1	L	1	5	73	0	12		0	0	0	8 None	None	No	No
1	12522	48330783	Caucas	ian	Female	3]	30-90)	85	2	2	1	13	68	2	28		0	0	0	8 None	None	No	No
1	15738	63555939	Caucas	lan	Female	[9	90-100)	95	3	3	3	12	33	3	18		0	0	0	8 None	None	No	No
2	28236	89869032	African	American	Female	[4	40-50)	45	1	1	1	9	47	2	17		0	0	0	9 None	None	No	No
3	36900	77391171	African.	American	n Male	[6	50-70)	65	2	2	1	7	62	0	11		0	0	0	7 None	None	No	No
4	10926	85504905	Caucas	ian	Female	[4	40-50)	45	1	L	3	7	60	0	15		0	1	0	8 None	None	Steady	Up
4	12570	77586282	Caucas	ian	Male	[8	30-90)	85	1	L	6	10	55	1	31		0	0	0	8 None	None	No	No
e	62256	49726791	African.	American	Female	[6	50-70)	65	3	3	1	1	49	5	2		0	0	0	8 None	None	No	No
7	73578	86328819	African	American	Male	[6	50-70)	65	1	L	3	12	75	5	13		0	0	0	9 None	None	No	No
7	7076	92519352	African	American	Male	[8	50-60)	55	1	L	1	4	45	4	17		0	0	0	8 None	None	No	No
8	34222 1	108662661	Caucas	ian	Female	[!	50-60)	55	1	L	1	3	29	0	11		0	0	0	3 None	None	No	No
8	39682 1	107389323	African	American	Male	5	70-80)	75	1	L	1	5	35	5	23		0	0	0	9 None	None	No	No
18	32796	63000108	African	American	Female	[7	70-80)	75	2	2	1	2	47	0	12		0	0	0	8 None	None	No	No
18	33930 1	107400762	Caucas	ian	Female	[8	30-90)	85	2	2	6	11	42	2	19		0	0	0	8 None	None	No	No
21	16156	62718876	African	American	Female	[7	70-80)	75	3	3	1	3	19	4	18		0	0	0	6 None	None	No	No
22	21634	21861756	Other		Female	[8	50-60)	55	1	L	1	1	33	0	7		0	0	0	3 None	None	Steady	No
23	36316	40523301	Caucas	ian	Male	[8	30-90)	85	1	L	3	6	64	3	18		0	0	0	7 None	>7	Steady	No
chlorpro	glimep	pir acetohe	examid	glipizid	glyburid	tolbutamid	l pioglit	azon rosigli	itazon acar	bos r	miglito	troglitazon	tolazamic	d examid	citoglipto	insuli	(lyburide- netformi (lipizide-	gumepiria e- pioglitazon	metformin- rosiglitazo	metformin- pioglitazo	cnang e in medic o	liabetesM
chlorpro pamide	glimep ide	pir acetohe	examid	glipizid e	glyburid e	tolbutamid e	e No	azon rosigli e	itazon acar e	bos r	miglito I	troglitazon e	tolazamio e	e examid	citoglipto n	insuli n	glyburide- metformi g	glipizide- metformin	gumepiria e- pioglitazon e	metformin- rosiglitazo ne	metformin- pioglitazo ne	e in medic ation	fiabetesM
chlorpro pamide No	glimep ide No	pir acetohe e No	examid	glipizid e No	glyburid e No	tolbutamid e No	e No	tazon rosigli e No	itazon acar e No	bos r l	miglito I No	troglitazon e No	tolazamio e No	e examid	citoglipto n No	insuli n No	glyburide- metformi g n n n	glipizide- metformin	gumepina e- pioglitazon e No	metformin- rosiglitazo ne No	metformin- pioglitazo ne No	e in medic of ation of No i	liabetesM 1 Jo
chlorpro pamide No No	glimep ide No No	pir acetohe e No No	examid	glipizid e No No Steady	glyburid e No No	tolbutamid e No No	e No No	tazon rosigli e No No	itazon acar e No No	bos r l	miglito I No No	troglitazon e No No No	tolazamio e No No	e examid e No No	citoglipto n No No	insuli n No Up	glyburide- metformi g n r No r No r	glipizide- metformin No No	gumepina e- pioglitazon e No No	metformin- rosiglitazo ne No No	metformin- pioglitazo ne No No	e in medic of ation of Yes Y	fiabetesM f No 'es
chlorpro pamide No No No	glimep ide No No No	pir acetohe: e No No No	examid	glipizid e No No Steady	glyburid e No No No	tolbutamid e No No No	Pioglit e No No No	azon rosigli e No No No	itazon acar e No No No	bos r l l	miglito l No No No	troglitazon e No No No	tolazamic e No No No	e examid e No No No No	citoglipto n No No No No	insuli n No Up No	glyburide- netformi No r No r No r	glipizide- metformin No No No	gumepina e- pioglitazon e No No No	metformin- rosiglitazo ne No No No	metformin- pioglitazo ne No No No No	e in medic d ation d No n Yes n Yes n	liabetesM 1 No Yes Yes
chlorpro pamide No No No No No	glimep ide No No No No	pir acetohe: e No No No No No	examid	glipizid e No No Steady No Steady	glyburid e No No No No No	tolbutamid e No No No No	e No No No No No No	azon rosigli e No No No No No	itazon acar e No No No No No	bos r l r	miglito I No No No No No	troglitazon e No No No No No	tolazamic e No No No No No	e No No No No No	citoglipto n No No No No No	insuli n No Up No Up Steady	glyburide- netformi g No f No f No f No f No f	glipizide- netformin No No No No	gumepina e- pioglitazon e No No No No No	metformin- rosiglitazo ne No No No No No	metformin- pioglitazo ne No No No No No	cnang e in medic ation No Yes Yes Yes	liabetesM I No fes fes 'es 'es
chlorpro pamide No No No No No No	glimep ide No No No No No	pir acetohe: e No No No No No No	examid	glipizid e No No Steady No Steady No	glyburid e No No No No No No	tolbutamid e No No No No No	e No No No No No No No	tazon rosigli e No No No No No	itazon acar e No No No No No No	bos r l r r	miglito L No No No No No	troglitazon e No No No No No No	tolazamic e No No No No No No	examid e No No No No No No	citoglipto n No No No No No No	insuli n No Up No Up Steady Steady	glyburide- netformi g No f No f No f No f No f No f No f	glipizide- netformin No No No No No No	gumepina e- pioglitazon e No No No No No No No	metformin- rosiglitazo ne No No No No No No	metformin- pioglitazo ne No No No No No No	cnang e in medic d ation d No 7 Yes 7 Yes 7 Yes 7 Yes 7 No 7	liabetesM I No fes fes fes fes fes
chlorpro pamide No No No No No No No	glimep ide No No No No No Steady	pir acetohe: e No No No No No No No Vo Vo	examid	glipizid e No No Steady No Steady No No	glyburid e No No No No No No No	tolbutamid e No No No No No No	I pioglit e No No No No No No No No	tazon rosigli e No No No No No No No	itazon acar e No No No No No No No	bos r l r r r	miglito I No No No No No No	troglitazon e No No No No No No No	tolazamic e No No No No No No No	e examid e No No No No No No No No	citoglipto n No No No No No No	insuli n No Up No Up Steady Steady Steady	glyburide- netformi N	glipizide- netformin No No No No No No No	gumepina e- pioglitazon e No No No No No No No	metformin- rosiglitazo ne No No No No No No No	metformin- pioglitazo ne No No No No No No No	cnang e in medic d ation d No 1 Yes Y Yes Y Yes Y No Yes Y	liabetesM I No fes fes fes 'es 'es 'es
chlorpro pamide No No No No No No	glimep ide No No No No No Steady No	pir acetohe: e No No No No No y No No	examid	glipizid e No No Steady No Steady No No No	glyburid e No No No No No No Steady	tolbutamid e No No No No No No No	I piogliti e No No No No No No No No No	azon rosigli e No No No No No No No	itazon e No No No No No No No No	bos r l r r r	miglito I No No No No No No No No	troglitazon e No No No No No No No	tolazamic e No No No No No No No No	e examid e No No No No No No No No No No	citoglipto n No No No No No No No	insuli n No Up No Up Steady Steady No	glyburide- netformi N N N N N N N N N N N NO	glipizide- metformin No No No No No No No No	gumepina e- pioglitazon e No No No No No No No No	metformin- rosiglitazo ne No No No No No No No No	metformin- pioglitazo ne No No No No No No No No	cnang e in medic o ation o No r Yes Y No Y Yes Y No Y Yes No	liabetesM J No res res res res res res res
chlorpro pamide No No No No No No No No	glimep ide No No No No Steady No No	pir acetohe: e No No No No No y No No No	examid	glipizid e No No Steady No No No Steady No Steady	glyburid e No No No No No No Steady No	tolbutamid e No No No No No No No	Pioglitt e No No No No No No No No No No	tazon rosigli e No No No No No No No No No No	itazon e No No No No No No No No No No	bos r l r r r r r	miglito I No No No No No No No No No	troglitazon e No No No No No No No	tolazamic e No No No No No No No No No	e examid e No No No No No No No No No	citoglipto n No No No No No No No No	insuli n No Up No Up Steady Steady Steady No Steady	styburide- netformi s No 1 No 1 No 1 No 1 No 1 No 1 No 1 No 1	glipizide- metformin No No No No No No No No No	gumepina e- pioglitazon e No No No No No No No No No	metformin- rosiglitazo ne No No No No No No No No	metformin- pioglitazo ne No No No No No No No No No	cnang e in medic d ation d Yes Yes Yes Yes Yes Yes Yes Yes Yes	diabetesM 1 Vo res res res res res res res res res
chlorpro pamide No No No No No No No No No	glimep Ide No No No No Steady No No No	Pir acetohe: e No No No No No No No No No No No	examid	glipizid e No No Steady No No No Steady No Steady No	glyburid e No No No No No Steady No No	tolbutamid e No No No No No No No No	Pioglitt e No No No No No No No No No No No	tazon rosigli e No No No No No No No No No Stead	itazon e No No No No No No No No No No No	bos r l r r r r r r r	miglito I No No No No No No No No No	troglitazon e No No No No No No No No	tolazamio e No No No No No No No	d examid e No No No No No No No No No No No	citoglipto n No No No No No No No No	insuli n No Up No Up Steady Steady Steady No Steady Steady	Styburide- netformi 1 N 1 NO 1	glipizide- metformin No No No No No No No No No No No No	gumepina e- pioglitazon e No No No No No No No No No No No No	metformin- rosiglitazo ne No No No No No No No No No	metformin- pioglitazo ne No No No No No No No No No No No No	cnang e in medic d ation d Yes Yes Yes No Yes Yes Yes Yes Yes	diabetesM J No fes fes fes fes fes 'es 'es 'es 'es 'es
chlorpro pamide No No No No No No No No	glimep ide No No No No Steady No No No No	pir acetohes e No No No No No No No No No No No No No	examid	glipizid e No No Steady No No Steady No Steady No No	glyburid e No No No No Steady No No No	tolbutamid e No No No No No No No No No No	l pioglit e No No No No No No No No No No No	tazon rosigli e No No No No No No No Stead No	ttazon acar e No No No No No No No No No No No No	bos r l r r r r r r r r r r r r r	miglito I No No No No No No No No No No	troglitazon e No No No No No No No No No No No	tolazamic e No No No No No No No No No	d examid e No No No No No No No No No No No No	citoglipto n No No No No No No No No	insuli n No Up No Up Steady Steady No Steady Steady Steady Steady	styburide- metformi n No 1	glipizide- netformin No No No No No No No No No No	gumepina e- pioglitazon e No No No No No No No No No No No No No	metformin- rosiglitazo ne No No No No No No No No No No	metformin- pioglitazo ne No No No No No No No No No No No	cnang e in medic ation of Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes	diabetesM i No fes fes fes fes fes fes fes ies ies ies ies ies
chlorpro pamide No No No No No No No No No	glimep ide No No No No No Steady No No No No	e No No No No No No No No No No No No No	examid	glipizid e No No Steady No No Steady No Steady No No No	glyburid e No No No No Steady No No No Up	tolbutamid e No No No No No No No No No No No	I piogliti e No No No No No No No No No No No No	tazon rosigil e No No No No No No No Stead No No No	ttazon acar e No No No No No No No y No No No No No No		miglito I No No No No No No No No No No No No No	troglitazon e No No No No No No No No No No No	tolazamic e No No No No No No No No No	examid e No No No No No No No No No No No No	citoglipto n No No No No No No No No No	insuli n No Up No Up Steady Steady No Steady Steady Steady Steady Steady	styburide- metformi n N 1 No 1	glipizide- netformin No	gumepina e- pioglitazon e No No No No No No No No No No No No No	metformin- rosiglitazo ne No No No No No No No No No No No No	metformin- pioglitazo ne No No No No No No No No No No No No No	cnang ein medic ation No Yes No Yes No Yes No Yes No Yes No Yes No Yes	diabetesM t Vo fes fes fes fes fes fes fes fes es 'es 'es 'es 'es
chlorpro pamide No No No No No No No No No No	glimep ide No No No No Steady No No No No No No	acetohe: e No	examid	glipizid e No No Steady No Steady No Steady No Steady No No No No	glyburid e No No No No No Steady No No No Up No	tolbutamid e No No No No No No No No No No No No	A piogliti e No No No No No No No No No No No No No	tazon rosigli e No No No No No No No Stead No No No No No	tazon acar e No No No No No No y No No No No No No No		miglito I No No No No No No No No No No No No No	troglitazon e No No No No No No No No No No No No No	tolazamic e No No No No No No No No No No No No	e examid e No No No No No No No No No No No No No	citoglipto n No No No No No No No No No No No	insuli n No Up Vo Steady Steady Steady Steady Steady Steady Steady Steady Steady Down	styburide- metforming No	glipizide- netformin No	gumepina e- pioglitazon e No No No No No No No No No No No No No	metformin- rosiglitazo ne No No No No No No No No No No No No No	metformin- pioglitazo ne No No No No No No No No No No No No No	cnang e in medic of ation of Yes No Yes Y Yes No Yes Y Yes Y Yes Y Yes Y Yes Y Yes Y Yes Y	diabetesM d Vo fes fes fes fes fes fes fes fes fes es ies ies ies ies ies
chlorpro pamide No No No No No No No No No No No No No	glimep ide No No No No Steady No No No No No No No No	acetohe: e No	examid	glipizid e No No Steady No Steady No No Steady No Steady No No No No No	glyburid e No No No No No Steady No No Up No No	tolbutamid e No No No No No No No No No No No No No	A piogliti e No No No No No No No No No No No No No	tazon rosigli e No No No No No No Stead No No No No No No No No No	ttazon e No No No No No No Y No No No No No No No		miglito I No No No No No No No No No No No No No	troglitazon e No No No No No No No No No No No No No	tolazamic e No No No No No No No No No No No No No	e examid e No No No No No No No No No No No No No	citoglipto n No No No No No No No No No No No No	insuli n No Up No Steady Steady Steady Steady Steady Steady Steady Steady Steady Steady Steady Steady Steady	Styburide- netformi n No	glipizide- metformin No	gumepina e- pioglitazon e No No No No No No No No No No No No No	metformin- rosiglitazo ne No No No No No No No No No No No No No	metformin- ploglitazo ne No	cnang e in medic ation No Yes Yes Yes Yes No Yes No	diabetesM d No fes fes fes fes fes fes fes fes fes fes
chlorpro pamide No No No No No No No No No No No No No	glimep ide No No No No Steady No No No No No No No No No	acetohe: e No	examid	glipizid e No No Steady No Steady No No No No No No No No No	glyburid e No No No No No Steady No No No No No No No No No No No	tolbutamid e No No No No No No No No No No No No No	I pioglit e No No No No No No No No No No No No No	azon rosigu e No No No No No No No No No No No No No	ttazon acar e No No No No No No No No No No No No No		miglito I No No No No No No No No No No No No No	troglitazon e No No No No No No No No No No No No No	tolazamic e No No No No No No No No No No No No No	examid e No No No No No No No No No No No No No	citoglipto n No No No No No No No No No No No No No	insuli n No Up Steady Steady Steady Steady Steady Steady Steady Steady Steady Steady Steady Steady Steady	slyburide- metformi n n n n n n n n n n n n n n n No n	glipizide- metformin No	gumepina e- pioglitazon e No No No No No No No No No No No No No	metformin- rosiglitazo ne No	metformin- ploglitazo ne No	cnang e in medic of ation of Yes No Yes No No Yes No Yes No No Yes No	diabetesM d Vo fes fes fes fes fes fes fes fes fes fes
chlorpro pamide No No No No No No No No No No No No No	glimep ide No No No No Steady No No No No No No No No No No	initial acetohesis e No	examid	glipizid e No Steady No Steady No Steady No Steady No No No No No No No	glyburid e No No No No Steady No No No Up No No No No No No No	tolbutamid e No No No No No No No No No No No No No	Piogliti e No No No No No No No No No No No No No	tazon rosigili e No No No No No No Stead No No No No No No No No No No No No	ttazon acar e No No No No No No y No No No No No No No No No No No No No		miglito I No No No No No No No No No No No No No	troglitazon e No No No No No No No No No No No No No	tolazamic e No No No No No No No No No No No No No	e examid e No No No No No No No No No No No No No	citoglipto n No No No No No No No No No No No No No	insuli n No Up No Up Steady St	Styburide- metformi Style n 1 No 1	glipizide- metformin No	gumepina e- pioglitazon e e No No No No No No No No No No No No No	metformin- rosiglitazo ne No No No No No No No No No No No No No	metformin- pioglitazo ne No No No No No No No No No No No No No	cnang e in medic ation Ves Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes	diabetesM d No fes fes fes fes fes fes fes fes fes fes
chlorpro pamide No No No No No No No No No No No No No	glimep Ide No No No No Steady No No No No No No No No No No No No No	acetohes e No	examid	glipizid e No No Steady No Steady No No Steady No No No No No No No Steady No No No No	glyburid e No No No No No Steady No Steady No No No No No No No No No	tolbutamid e No No No No No No No No No No No No No	Pioglit e No No No No No No No No No No No No No	tazon rosigli e No No No No No No No No No No No No No	ttazon a car e No No No No No No No No No No No No No		miglito I NO NO NO NO NO NO NO NO NO NO	troglitazon e No No No No No No No No No No No No No	tolazamic e No No No No No No No No No No No No No	examid e No No No No No No No No No No No No No	citoglipto n No	insuli n No Up Steady Steady Steady Steady Steady Steady Steady Steady Steady Steady Up Steady Steady Steady Steady	Styburide- metforming No 1	glipizide- metformin No	Build biglitazon piglitazon No	metformin- rosiguitazo ne No No No No No No No No No No No No No	metformin- piogitazo ne No No No No No No No No No No No No No	cnang e in medic ation Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes	diabetesM No fes fes fes fes fes fes fes fes fes fes
chlorpro pamide No No No No No No No No No No No No No	glimep ide No No No No Steady No No No No No No No No No No No No No	acetone: e No	xamid	glipizid e	glyburid e No No No No Steady No No No No No No No No No Steady	tolbutamid e No No No No No No No No No No No No No	I piogliti e No No No No No No No No No No No No No	tazon rosigil e No No No No No No No No No No No No No	tazon acar e No No No		miglito I No No No No No No No No No No No No No	troglitazon e No No No No No No No No No No No No No	tolazamic e No No No No No No No No No No No No No	examid e No No No No No No No No No No No No No	citoglipto n No	insuli n No Up No Up Steady Steady Steady Steady Steady Steady Steady Up Steady Down Steady No	Styburide- metformi Style No 1	glipizide- metformin No	gumepina e- pioglitazon e No	metformin- rosigitazo ne No No No No No No No No No No No No No	metformin pioglitazo ne No	chang ein medic ation Yes No Yes No Yes Yes Yes No Yes Yes No Yes Yes Yes Yes No Yes Yes Yes No Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes	diabetesM d No res res res res res res res res
chlorpro pamide No No No No No No No No No No No No No	glimep ide No No No No No No No No No No No No No	acetone: e No	xamid	glipizid e No Steady No Steady No Steady No No No No No No No Steady No Steady No No No No No No No No	glyburid e No No No No No No No No No No No No No	tolbutamid e No No No No No No No No No No No No No	I pioglith e No No No No No No No No No No No No No	tazon rosigil e No No No No No No Stead No No No No No No No No No No No No No	ttazon e e No No No No No No No No No No No No No		miglito L NO NO NO NO NO NO NO NO NO NO	troglitazon e No No No No No No No No No No No No No	tolazamia e No No No No No No No No No No No No No	examid e No No No No No No No No No No No No No	citoglipto n No	insuli n No Up Steady Steady Steady Steady Steady Steady Steady Steady Steady Up Steady Up Steady St	Ityburide- metform Ityburide- metform No 1	glipizide- metformin No No	Build and a second an	metformin rosiglitazo ne No No No No No No No No No No No No No	metformin- ploglitazo ne No No No No No No No No No No No No No	chang ein medic ation Yes No Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes	diabetesM d No fes fes fes fes fes fes fes fes
chlorpro pamide No	glimep ide No No No No Steady No No No No No No No No No No No No No	acetone: e No	xamid	glipizid e	glyburid e No No No No No Steady No No No No No Steady No Steady No No No No	tolbutamid e No No	I pioglitt e No No No No No No No No No No No No No	tazon rosigili e No No No No No No Stead No No No No No No No No No No No No No	tazon acar e No No No		miglito I I N0 I N0	troglitazon e No No No No No No No No No No No No No	tolazamic e No No No No No No No No No No No No No	e examid e No No No No No No No No No No No No No	citoglipto n No	insuli n No Up Steady Steady Steady Steady Steady Steady Down Steady Down Steady Up Steady No Steady No No	Styburide- metformi 1 No 1 <td>glipizide- metformin No No</td> <td>Building e- ploglitazon e No No</td> <td>metformin metformin ne ne No No</td> <td>metformin- pioglitazo ne No No</td> <td>cnang ein medic No No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes</td> <td>diabetesM d No res res res res res res res res res res</td>	glipizide- metformin No	Building e- ploglitazon e No	metformin metformin ne ne No	metformin- pioglitazo ne No	cnang ein medic No No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes	diabetesM d No res res res res res res res res res res
chlorpro pamide No No No No No No No No No No No No No	glimep ide No No No No Steady No No No No No No No No No No No No No	acetone: e No	xamid	glipizid e No No Steady No Steady No Steady No No No No No No No No No No No No No	glyburid e No No No No No Steady No No No No No No No Steady No Steady No No No No No No No No No No No No No	tolbutamid e No No No No No No No No No No No No No	I pioglit e No No	tazon rosigili e No No No No No No No No No No No No No	tazon acar e No No No No No No No No No No No No No		miglito I I N0	troglitazon e No	tolazamic e No No No No No No No No No No No No No	examid e No No No No No No No No No No No No No	citoglipto n No	insuil n No Up Steady Steady Steady Steady Steady Steady Down Steady Up Steady No Steady No Steady No Steady No	Styburide- metforming No	glipizide- metformin No	Building e- pioglitazon e no	metformin rosiglitazo ne No No No No No No No No No No No No No	metformin- plogitazo ne No	change change e in a e in a e in a ation a Yes b Yes<	diabetesM d Vo fes fes fes fes fes fes fes fes fes fes
chlorpro pamide No No	glimep ide No No No No Steady No No No No No No No No No No No No No	acetohe: e No	XXX	glipizid n No 1 Steady 1 No 1 Steady 1 No 1 Steady 1	glyburid e No No No No No Steady No Steady No No No No No No No No No No No No No	tolbutamid e No	I pioglitt e No No No No No No No No No No No No No	tazon rosigiti e No No No No No No Stead No No No No No No No No No No No No No	tazon acar No No		miglito I I I I I I I I I I I I I I I I I I I	troglitazon e No No No No No No No No No No No No No	tolazamik e No No No No No No No No No No No No No	examid e No No No No No No No No No No No No No	citoglipto n No	Insul No Up Steady Steady Steady Steady Steady Steady Steady Steady Steady Steady Steady Steady Steady No Steady Steady No Steady No Steady SteadStead Stada SteadSteadSteadSteadSteadSteadSteadStead	styburide- metformi n n n	glipizide- metformin No	Building e proglitazon e Positivazon e No No <	metformin- rosiglitazo ne No	metformin- plogitazo ne No	cname cname ein medica d Mail n n No 1 n Yes 1 n No 1 n No 1 n Yes 1 n Yes 1 n No 1 n Yes 1 n	diabetesM J Vio res res
chlorpro pamide No	glimep ide No No No No Steady No No No No No No No No No No No No No	acetohe: e No No	xxamid	glipizid glipizid No No No Steady No Steady No Steady No No Steady No No No No No No No No No Steady No Steady No No No	glyburid e No No No No Steady No No No No Steady No Steady No No No No No No No No No No No No No	tolbutamid e No No No No No No No No No No No No No	I pioglith e No No No No No No No No No No No No No	tazon rosigu e No No No No No No No No No No No No No	tazon acar No No		miglito L L NO	troglitazon e No No	tolazamic e No No No No No No No No No No No No No	examid e No No	citoglipto n No	insuli n No Up Steady Steady Steady Steady Steady Steady Steady Steady Steady No Steady No Steady No Steady No Steady No Steady No Steady No Steady Steady No Steady No	Styburide netforming No	glipizide- metformin No	Buildential e- proglitazione e No	metformin- rosiglitazo ne No No	metformin- plogitazo ne No No	cname cname ein medica a No 1 n Ves 1 n Yes 1 n No 1 n Yes 1 n No 1 n No 1	diabetesM d No res res res res res res res res res res
chlorpro pamide No No No No No No No No No No No No No	glimep ide No No No Steady No No No No No No No No No No No No No	acetohe: e No	xxamid	glipizid glipizid	glyburid e No No No No Steady No No No No Steady No Steady No Steady No No Steady No No Steady No No	tolbutamid e No No No No No No No No No No No No No	I pioglitt e No No No No No No No No No No No No No	tazon rosiglu e No No No No No No No No No No No No No	tazon acar e No No No		miglito I N0	troglitazon e No No	tolazamic e No No No No No No No No No No No No No	4 examid e No No No No No No No No No No No No No	citoglipto n No No	insuli n No Up Steady Steady Steady Steady Steady Steady Steady Steady Steady No Steady No Steady No Steady No No No	Styburide n n No	glipizide- metformin No	Buildential e ploglitazon e No	metformin- rosiglitazo ne No No	metformin- plogitazo ne No	cname cname ein medica a medica a a No 1 b Yes 1 b No 1 b Yes 1 b	JiabetesM J No res res res res res res res res res res